 |
 |
 |
 |
 |
 |
 |
|
 |
 |
Board and InvestorsGenstruct is backed by industry leading investors including Flagship Ventures and Pappas Ventures (formerly A.M. Pappas & Associates). Our vision for systems biology has been successfully implemented to create significant value within drug discovery.Jim Matheson - Chairman Chairman Jim Matheson has been a general partner of Flagship Ventures since 2000. He has previously served for 15 years as an officer and fighter pilot in the U.S. Navy. His duties included being stationed on aircraft carriers flying combat missions in Iraq and Bosnia, as a TOPGUN Instructor, and as the Officer-in-Charge of the Navy's West Coast adversary training and evaluation squadron. Mr. Matheson also gained broad experience in emerging weapons system design, testing and procurement, and was deeply involved in many of the Navy's modern IT initiatives. He continues to serve as a commander in the U.S. Naval Reserves. Mr. Matheson earned a B.S. with Honors in computer science from the U.S. Naval Academy and an M.B.A. from Harvard Business School. to top Sean joined Pappas Ventures in 2006 after ten years of experience in business development, program management and research management in the biotech industry. Immediately prior to Pappas he served as Vice President of Business Development at SGX Pharmaceuticals Inc., an oncology-focused biotechnology company located in San Diego. Under his leadership SGX entered into a wide range of strategic partnerships with major pharmaceutical companies including a $515 million oncology alliance with Novartis focused on the development of novel therapies for chronic myelogenous leukemia. Prior to SGX, Sean was Associate Director of Program Management at Millennium Pharmaceuticals where he managed drug discovery programs. Prior to joining the Program Management group at Millennium, Sean managed an interdisciplinary team of scientists that developed novel genomic techniques for the identification of therapeutic proteins in the context of a major alliance with Eli Lilly. Sean is the author of 17 peer-reviewed scientific publications and an inventor on 29 issued patents and filed patent applications. to top Mike Pavia is an Entrepreneur-in-Residence with Oxford Bioscience Partners. Prior to joining Oxford in 2002, he was chief technology officer at Millennium Pharmaceuticals, where his major focus was to improve the productivity of the drug discovery and development process through the appropriate use of new technologies. Dr. Pavia has 20 years experience in pharmaceutical research and discovery. He was formerly vice president for Cambridge Research at Sphinx Pharmaceuticals, a division of Eli Lilly & Co., focusing on the development of combinatorial chemistry technologies. Prior to Sphinx, Dr. Pavia held senior scientific positions in the Department of Chemistry at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert. He holds a B.S. in chemistry from Lehigh University and a Ph.D. in organic chemistry from the University of Pennsylvania. to top Dr. Levine is a Professor in the School of Natural Sciences at the Institute for Advanced Study (IAS) and leads The Simons Center for Systems Biology at the Institute, which he established. Dr. Levine was on the faculty of the Biochemistry Department of Princeton University from 1968 to 1979, when he became chair and professor in the Department of Microbiology at the State University of New York, Stony Brook, School of Medicine. Returning to Princeton University in 1984, he was named Harry C. Weiss Professor in the Life Sciences in the Department of Molecular Biology, a position he held until 1998. He chaired the Department between 1984 and 1996. He was President and Chief Executive Officer of the Rockefeller University in New York City from 1998 to 2002, as well as Heilbrunn Professor of Cancer Biology and laboratory head until joining the Institute in 2002. Dr. Levine is a graduate of Harpur College, State University of New York, and earned his PhD in microbiology from the University of Pennsylvania School of Medicine. Subsequently he was postdoctoral fellow of the Public Health Service at the California Institute of Technology. He holds honorary degrees from, among other institutions, Rider University, the University of Medicine and Dentistry of New Jersey, the Weizmann Institute of Science, and the University Pierre and Marie Curie in Paris. to top Chris Varma joined Flagship Ventures as a Partner in 2007, focusing primarily on Life Science investments. Prior to joining Flagship Chris had been with Novartis Pharmaceuticals since 2004, where he served most recently as Director on the Tekturna (aliskiren) marketing team responsible for Medical Marketing, Medical Strategy, and Professional Promotions activities. Before Novartis, Chris was a consultant for Millennium Pharmaceuticals, and prior to that worked for the US Food and Drug Administration (FDA) in the Office of Combination Products. Chris holds a Ph.D. in Biomedical Engineering from the Harvard-MIT Division of Health Sciences & Technology (HST), a M.S. in Management from Stanford University, and both a M.S. and B.S. in Computer Science from Stanford University. to top |
 |
|
 |
| One Alewife Center | Cambridge, MA 02140 | (617) 547-5421 | sitemap |